41680-09-5

Usage

Uses

Used in Pharmaceutical Industry:
Liquiritigenin is used as a therapeutic agent for its anti-inflammatory properties, helping to reduce inflammation and oxidative stress, which are common in various health conditions.
Used in Cancer Treatment:
Liquiritigenin is used as an anti-cancer agent, particularly for its ability to inhibit the growth and spread of cancer cells. It has shown promise in laboratory studies and may be a potential candidate for further research and development in oncology.
Used in Nutraceutical Industry:
Liquiritigenin is used as a dietary supplement or functional food ingredient due to its antioxidant properties, which can contribute to overall health and well-being by combating oxidative stress.
Used in Research and Development:
Liquiritigenin is used as a subject of study in ongoing research to explore its potential applications in treating diseases such as diabetes and cardiovascular disorders, as well as its general health benefits.
Used in Cosmetic Industry:
Although not explicitly mentioned in the provided materials, given its anti-inflammatory and antioxidant properties, Liquiritigenin could potentially be used in the cosmetic industry for skin care products aimed at reducing inflammation and oxidative stress, thereby promoting skin health and appearance.

Upstream product

• 961-29-5 isoliquirtigenin 
• 551-15-5 liquiritin(sh) 
• 25826-69-1 4',7-dimethoxyflavanone 
• 7664-93-9 sulfuric acid 
• 551-15-5 liquiritin 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 123-08-0 4-hydroxy-benzaldehyde 
• 69097-97-8 7,4'-dihydroxy-dihydroflavone 
• 943-89-5 (E)-3-(4-methoxyphenyl)acrylic acid 
• 151-10-0 1,3-Dimethoxybenzene 
• 20034-62-2 2'-Hydroxy-4'-(aethoxy-methoxy)-acetophenon 
• 32568-59-5 4-vinylphenyl benzoate 
• 124775-22-0 1-<2-Hydroxy-4-(methoxymethoxy)phenyl>-3-<4-(methoxymethoxy)phenyl>prop-2-en-1-on 
• 65490-08-6 2-hydroxy-4-(methoxymethoxy)acetophenone 

Downstream Products

• 101097-68-1 liquiritigenin oxime 
• 578-86-9 liquiritigenin 
• 59870-65-4 Glabrol 
• 59870-65-4 glabrol 
• 78316-26-4 4'-hydroxy-7-O-prenylflavanone 
• 131887-80-4 (2R,3S)-2,7,4'-trihydroxyisoflavanone 

Relevant academic research and scientific papers

Liquiritigenin inhibits hepatic fibrogenesis and TGF-β1/Smad with Hippo/YAP signal

Background: Recent reports highlighted the possibility that Yes-associated protein (YAP) and transforming growth factor-β1 (TGF-β1) can act as critical regulators of hepatic stellate cells (HSCs) activation; therefore, it is natural for compounds targeting Hippo/YAP and TGF-β1/Smad signaling pathways to be identified as potential anti-fibrotic candidates. Purpose: Liquiritigenin (LQ) is an aglycone of liquiritin and has been reported to protect the liver from injury. However, its effects on the Hippo/YAP and TGF-β1/Smad pathways have not been identified to date. Methods: We conducted a series of experiments using CCl4-induced fibrotic mice and cultured LX-2 cells. Result: LQ significantly inhibited liver fibrosis, as indicated by decreases in regions of hepatic degeneration, inflammatory cell infiltration, and the intensity of α-smooth muscle actin (α-SMA) staining in mice. Moreover, LQ blocked the TGF-β1-induced phosphorylation of Smad 3, and the transcript levels of plasminogen activator inhibitor-1 (PAI-1) and matrix metalloproteinase-2 (MMP-2) in LX-2 cells, which is similar with resveratrol and oxyresveratrol (positive controls). Furthermore, LQ increased activation of large tumor suppressor kinase 1 (LATS1) with the induction of YAP phosphorylation, thereby preventing YAP transcriptional activity and suppressing the expression of exacerbated TGF-β1/Smad signaling molecules. Conclusion: These results clearly show that LQ ameliorated experimental liver fibrosis by acting on the TGF-β1/Smad and Hippo/YAP pathways, indicating that LQ has the potential for effective treatment of liver fibrosis.

FLAVONOID GLUCOSIDES FROM LICORICE

Two new flavanone glycosides, liquiritigenin 4'-apiosyl(1->2)-glucoside and liquiritigenin 7,4'-diglucoside together with a known flavone, apigenin 6,8-di-C-glucoside, have been isolated from licorice.Key Word Index- Glycyrrhiza uralensis; Leguminosae; li

Cloning and functional characterization of a chalcone isomerase from trigonella foenum-graecum L

Flavonoids belong to a group of plant natural products with variable phenolic structures and play important roles in protection against biotic and abiotic stress. Fenugreek (Trigonella foenum-graecum L.) seeds and stems contain flavonol glycosides and isoflavone derivatives. Up to now, the molecular features of fenugreek flavonoid biosynthesis have not been characterized. Here we present cloning of a cDNA encoding a chalcone isomerase (namely TFGCHI1) from the leaves of T. foenum-graecum which convert chalcones to flavanones in vitro. Transformation of Arabidopsis loss-of-function tt5 (chi) mutant with a TFGCHI1 cDNA complemented tt5 and produced higher levels of flavonol glycosides than wild-type Col-0. Georg Thieme Verlag KG Stuttgart · New York.

Design, synthesis, and cholinesterase inhibition assay of liquiritigenin derivatives as anti-Alzheimer's activity

The marine environment is a rich resource for discovering functional materials, and seaweed is recognized for its potential use in biology and medicine. Liquiritigenin has been isolated and identified from Sargassum pallidum. To find new anti-Alzheimer's activity, we designed and synthesized thirty-two 7-prenyloxy-2,3-dihydroflavanone derivatives (3a-3p) and 5-hydroxy-7-prenyloxy-2,3-dihydro-flavanone derivatives (4a-4p) as cholinesterases inhibitors based on liquiritigenin as the lead compound. Inhibition screening against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) indicated that all synthesized compounds possessed potent AChE inhibitory activity and moderated to weak BuChE inhibitory activity in vitro. Kinetic studies demonstrated that compound 4o inhibited AChE via a dual binding site ability. In addition, all compounds displayed the radical scavenging effects. Finally, the molecular docking simulation of 4o in AChE active site displayed good agreement with the obtained the pharmacological results.

Synthesis and studies of flavone and bis-flavone derivatives

Flavonoids are widely occurring polyphenols of plant origin and well explored in the field of pharmacological activities. Recent studies showed this scaffold to be more dynamic as fluorescent probe. Very rare reports are there in literature on flavones as liquid crystals, for the first time we have synthesized and characterized flavone and bis-flavone derivatives for mesomorphic properties. Compounds 9a–d and 13a–d were studied for liquid crystalline properties by Differential scanning calorimetry (DSC) and Polarizing optical microscopy (POM) studies. The compounds 8, 9a–d, 12, and 13a–d were also studied for antioxidant property by DPPH assay.

A method of synthesizing the glycyrrhizin (by machine translation)

The invention relates to a synthetic chemical method of glycyrrhizin. In order to 2, 4 - dihydroxy acetophenone and 4 - hydroxy benzoic acid ethyl ester as the raw material, the protective group for a hydroxyl, keto ester condensation, cyclization and hyd

Identification of metabolites of liquiritin in rats by UHPLC-Q-TOF-MS/MS: Metabolic profiling and pathway comparison: In vitro and in vivo

Liquiritin (LQ), the main bioactive constituent of licorice, is a common flavoring and sweetening agent in food products and has a wide range of pharmacological properties, including antidepressant-like, neuroprotective, anti-cancer and anti-inflammatory properties. This study investigated the metabolic pathways of LQ in vitro (rat liver microsomes) and in vivo (rat model) using ultra high-performance liquid chromatography coupled with hybrid triple quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF-MS/MS). Moreover, supplementary tools such as key product ions (KPIs) were employed to search for and identify compounds. As a result, 56 in vivo metabolites and 15 in vitro metabolites were structurally characterized. Oxidation, reduction, hydrolysis, methylation, acetylation, and sulfate and glucuronide conjugation were determined to be the major metabolic pathways of LQ, and there were differences in LQ metabolism in vitro and in vivo. In addition, the in vitro and in vivo metabolic pathways were compared in this study.

METHOD FOR PRODUCING LIQUIRITIGENIN PRECURSOR

An objective of this invention is to provide a mass manufacturing method for providing liquiritigenin by a proper method. The present invention provides a method for producing isoliquiritigenin by bringing a 4-alkoxy cinnamic acid represented by formula (I) and a 1,3-alkoxybenzene represented by formula (II) into Friedel-Crafts reaction (A) for coupling to a trialkoxy isoliquiritigenin represented by a synthesis formula (III) and allowing it to be crystal, and removing protection group to obtain an isoliquiritigenin represented by formula (IV), wherein, an in situ liquiritigenin (-) pharmacological effect is obtained by administrating the isoliquiritigenin represented by formula (IV)as a precursor of liquiritigenin into body.

METHOD FOR PRODUCING LIQUIRITIGENIN PRECURSOR

PROBLEM TO BE SOLVED: To provide a method which is suitable as a mass production method of liquiritigenin. SOLUTION: Provided is a method for producing liquiritigenin, comprising: synthesizing and crystallizing a trialkoxy-isoliquiritigenin represented by a formula (iii) by coupling a 4-alkoxycinnamic acid represented by a formula (i) and a 1,3-alkoxybenzene represented by a formula (ii) by a Friedel-Craft reaction (A); and eliminating a protective group to obtain isoliquiritigenin represented by a formula (iv). The isoliquiritigenin represented by a formula (iv) is administered in a body as a precursor of liquiritigenin represented by a formula (v), which is converted to a (-) form of liquiritigenin in the body. COPYRIGHT: (C)2016,JPOandINPIT

MICROBIAL PRODUCTION OF THE FLAVONOIDS GARBANZOL, RESOKAEMPFEROL AND FISETIN

The invention provides a genetically modified micro-organism comprising one or more transgene for the production of one or more of the flavonoids garbanzol, resokaempferol and fisetin. The micro-organism may be a bacterial or yeast cell engineered to express a metabolic pathway for garbanzol, resokaempferol and/or fisetin biosynthesis. The invention further provides a method for producing garbanzol, resokaempferol and/or fisetin employing the genetically modified micro-organism of the invention. The genetically modified micro- organism may be used to convert a number of substrates and/or co-substrates into fisetin via a fisetin biosynthetic pathway.